dc.contributor.author |
Asgin, Nergis |
|
dc.contributor.author |
Satilmis, Serife |
|
dc.date.accessioned |
2022-03-08T09:38:30Z |
|
dc.date.available |
2022-03-08T09:38:30Z |
|
dc.date.issued |
2019 |
|
dc.identifier.citation |
Asgin, N., & Satilmis, S. (2021). Evaluation of hepatitis B virus and Hepatitis C virus frequency in hemodialysis patients . Annals of Medical Research |
en_US |
dc.identifier.uri |
http://hdl.handle.net/11616/54732 |
|
dc.description.abstract |
Aim: This study aimed to investigate the prevalence of the hepatitis B virus and hepatitis C virus in patients undergoing hemodialysis in Karabuk city.Material and Methods: For patients presented to the Karabuk University Training and Research Hospital for hemodialysis between January 2016 and December 2018, HBsAg, anti-HBs, and anti-HCV assays were conducted using the chemiluminescence method and HBV DNA, HCV RNA and HCV genotyping tests were conducted using real-time polymerase chain reaction. The data was retrospectively evaluated.Results: Of 345 patients undergoing hemodialysis, 211 (61.2%) were male and 134 (38.8%) were female. The mean age of the patients was 62 (15–96) years. Moreover, 0.9% (n = 3) of patients were HBsAg positive and 4.3% (n = 15) were anti-HCV positive. Three patients with HBsAg positivity were also HBV DNA positive. Of the 15 patients who were anti-HCV positive, 12 were also HCV RNA positive. Of these, eight patients had the HCV genotype 1b and four patients had the genotype 4. Anti-HBs seropositivity was detected in 65.8% of patients. The highest Anti-HBs seropositivity rate was observed in patients aged 40 years (76%) and the difference between age groups was statistically significant (p = 0.002). Conclusion: In our study, the prevalence of HBsAg seropositivity in patients undergoing hemodialysis (0.9%) was lower than that reported by the Turkish Society of Nephrology (2.65%). This difference may arise from the high anti-HBs seropositivity rate. Conversely, the prevalence of anti-HCV seropositivity (4.3%) was similar to the mean prevalence in Turkey (4.2%). Infection prevention measures against viral hepatitis should be strictly implemented, especially in hemodialysis units. |
en_US |
dc.language.iso |
eng |
en_US |
dc.rights |
info:eu-repo/semantics/openAccess |
en_US |
dc.title |
Evaluation of hepatitis B virus and Hepatitis C virus frequency in hemodialysis patients |
en_US |
dc.type |
article |
en_US |
dc.relation.journal |
Annals of Medical Research |
en_US |
dc.contributor.department |
İnönü Üniversitesi |
en_US |